Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
R926112 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| R926112 | DRUG | - |
| Beclomethasone dipropionate | DRUG | - |
Inclusion Criteria: * Subjects must sign a written informed consent form and assent (if applicable) for study participation. * Males and females, 12 years of age or older * Subjects must have a history consistent with seasonal allergic rhinitis (SAR) during the fall pollen season for at least the p...
R926112 is an investigational small molecule being studied for the treatment of seasonal allergic rhinitis. It is intended for patients with symptomatic seasonal allergic rhinitis, a condition characterized by nasal symptoms triggered by allergens during specific seasons. The drug is currently in clinical development and has not been approved by regulatory authorities.
R926112 is being developed by Rigel Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol RIGL. The company is conducting clinical research to evaluate the safety and efficacy of R926112 in patients with seasonal allergic rhinitis.
R926112 is in Phase 2 clinical development. The drug has completed a Phase 2 trial in patients with symptomatic seasonal allergic rhinitis. As an investigational drug, it is still in clinical development and has not been approved for commercial use.
R926112 has been studied in one completed Phase 2 clinical trial, identified as NCT00115089. This trial was a 7-day study of the mast cell inhibitor R926112 in patients with symptomatic seasonal allergic rhinitis. The trial enrolled 375 participants aged 12 years and older.
R926112 is described as a mast cell inhibitor. Mast cells play a role in allergic responses by releasing histamine and other inflammatory mediators. By inhibiting mast cell activity, R926112 may help reduce the symptoms of seasonal allergic rhinitis. The drug is administered as a small molecule.
R926112 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for seasonal allergic rhinitis. The drug has completed a clinical trial, but it has not received regulatory approval for marketing or use in patients.